These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34001187)

  • 1. Gene alterations as predictors of radiation-induced toxicity in head and neck squamous cell carcinoma.
    Sumner W; Ray X; Sutton L; Rebibo D; Marincola F; Sanghvi P; Moiseenko V; Deichaite I
    J Transl Med; 2021 May; 19(1):212. PubMed ID: 34001187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline genetic biomarkers to stratify patients for personalized radiation treatment.
    Deichaite I; Hopper A; Krockenberger L; Sears TJ; Sutton L; Ray X; Sharabi A; Navon A; Sanghvi P; Carter H; Moiseenko V
    J Transl Med; 2022 Aug; 20(1):360. PubMed ID: 35962345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes.
    Romesser PB; Cahlon O; Scher ED; Hug EB; Sine K; DeSelm C; Fox JL; Mah D; Garg MK; Han-Chih Chang J; Lee NY
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):386-395. PubMed ID: 27084656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.
    Deneuve S; Bastogne T; Duclos M; Mirjolet C; Bois P; Bachmann P; Nokovitch L; Roux PE; Girodet D; Poupart M; Zrounba P; Claude L; Ferella L; Iacovelli NA; Foray N; Rancati T; Pereira S
    Tumori; 2023 Apr; 109(2):173-185. PubMed ID: 35578746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary clinical outcomes of head and neck squamous cell carcinoma treated with particle beam radiation therapy.
    Huang Q; Hu J; Hu W; Gao J; Yang J; Qiu X; Zhang H; Lu JJ; Kong L
    Cancer Med; 2023 Jun; 12(11):12128-12138. PubMed ID: 37039275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life assessment of Volumetric Modulated Arc Therapy (VMAT) toxicity in Head and Neck Squamous Cell Carcinoma (HNSCC) treatment.
    Moncharmont C; Vallard A; Mengue Ndong S; Guy JB; Saget C; Méry B; Langrand-Escure J; de Laroche G; Goyet D; Prades JM; Fournel P; Magné N
    Acta Otolaryngol; 2016; 136(2):181-8. PubMed ID: 26503806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
    Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
    Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia.
    Yahya N; Linge A; Leger K; Maile T; Kemper M; Haim D; Jöhrens K; Troost EGC; Krause M; Löck S
    Acta Oncol; 2022 Jul; 61(7):856-863. PubMed ID: 35657056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis.
    Haussmann J; Tamaskovics B; Bölke E; Djiepmo-Njanang FJ; Kammers K; Corradini S; Hautmann M; Ghadjar P; Maas K; Schuler PJ; Hoffmann TK; Lammering G; Budach W; Matuschek C
    Strahlenther Onkol; 2019 Dec; 195(12):1041-1049. PubMed ID: 31586229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses.
    Takiar V; Garden AS; Ma D; Morrison WH; Edson M; Zafereo ME; Gunn GB; Fuller CD; Beadle B; Frank SJ; William WN; Kies M; El-Naggar AK; Weber R; Rosenthal DI; Phan J
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1117-31. PubMed ID: 27354127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
    Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
    J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
    Foy JP; Bazire L; Ortiz-Cuaran S; Deneuve S; Kielbassa J; Thomas E; Viari A; Puisieux A; Goudot P; Bertolus C; Foray N; Kirova Y; Verrelle P; Saintigny P
    BMC Med; 2017 Sep; 15(1):165. PubMed ID: 28859688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results.
    Ghosh-Laskar S; Yathiraj PH; Dutta D; Rangarajan V; Purandare N; Gupta T; Budrukkar A; Murthy V; Kannan S; Agarwal JP
    Head Neck; 2016 Apr; 38 Suppl 1():E1481-7. PubMed ID: 26561342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate.
    Strojan P; Corry J; Eisbruch A; Vermorken JB; Mendenhall WM; Lee AW; Haigentz M; Beitler JJ; de Bree R; Takes RP; Paleri V; Kelly CG; Genden EM; Bradford CR; Harrison LB; Rinaldo A; Ferlito A
    Head Neck; 2015 Jan; 37(1):134-50. PubMed ID: 24481720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.